0001193125-26-149021
SEC filingQuince Therapeutics, Inc. filed a Certificate of Amendment effecting a 1-for-10 reverse stock split, effective April 10, 2026, with trading on a split-adjusted basis commencing April 13, 2026 on Nasdaq.
The reverse stock split consolidates every 10 shares of common stock into 1 share, reducing outstanding shares to approximately 16.3 million while preserving proportional ownership interests for all stockholders. This action, authorized by stockholders in June 2025 and executed by the board, addresses potential Nasdaq compliance needs by increasing the per-share price without altering the company's capital structure or common stock rights. Trading under the existing ticker QNCX will shift to a new CUSIP on April 13, 2026, with Equiniti Trust Company, LLC handling exchange processing. Stockholders holding via brokers will see automatic adjustments, while cash payments resolve fractional shares, minimizing administrative burdens.